国产高端仪器公司完成超亿元B+轮融资

Core Viewpoint - The recent financing round aims to accelerate the global business layout of Chao Wei Jing Bio Technology, focusing on exosomes and various types of nanoparticles, establishing a highly integrated fully automated separation and purification technology platform to transition from laboratory processes to an industrial-grade intelligent manufacturing system [1]. Group 1 - Chao Wei Jing has completed a B+ round financing exceeding 1 billion yuan, with investments from five institutions including Guangdong Traditional Chinese Medicine Health Fund and Beijing Pharmaceutical Health Industry Investment Fund [2]. - Since its establishment in 2016, Chao Wei Jing has been dedicated to the independent research and development of high-end brain science instruments, providing key solutions for life sciences, clinical medicine, and brain-computer interface fields [2]. - The financing will be utilized in three main areas: accelerating the R&D of next-generation products, deepening global market layout, and speeding up talent acquisition [2]. Group 2 - Chao Wei Jing will enhance its dual-driven strategy of "high-end scientific instruments + brain-computer interface" to further solidify its technological barriers [2]. - The company aims to promote the widespread application of high temporal and spatial resolution neural observation technology in clinical and brain disease intervention fields [2]. - This initiative will provide strong support for the independent and controllable development of high-end scientific research instruments in China [2].